Coumermycin was the most active agent in vitro against methicillin-resistant Staphylococcus aureus when compared with fusidic acid, imipenem, rifampin, trimethoprim-sulfamethoxazole, and vancomycin. The MICs of coumermycin ranged from 0.002 to >4 I,g/ml and from 0.5 to >4 ,ug/ml for inocula of 104 and 106 CFU/ml, respectively. The combination of coumermycin with either cephalothin or ciprofloxacin showed some synergy; antagonism was found with gentamicin.
CFU/ml. An antibiotic-free broth culture was used as the control. The MIC was defined as the lowest concentration that showed no visible growth after 18 to 24 h of incubation at 30°C. The MBC was determined by subculturing 0.01 ml of the inoculated broth, with a calibrated loop, onto 5% sheep blood agar plates (BBL). The MBC was defined as the lowest concentration resulting in 99.9% killing of the bacteria.
Synergy studies on 11 of the isolates were performed by the checkerboard microdilution method at a final inoculum of 104 CFU/ml. Synergy was defined by a fractional inhibitory concentration index of 0.5, and antagonism was defined by a fractional inhibitory concentration index of -2.0 (1).
Coumermycin was the most active antimicrobial agent against MRSA strains with a MIC for 90% of strains tested (MIC90) of 0.063 ,ug/ml at inoculum sizes of 102 and 104 CFU/ml. Fusidic acid had MIC90s of 0.312 ,ug/ml at an inoculum of 102 CFU/ml and 0.63 at 104 CFU/ml. The MIC90 * Corresponding author. was >4 ,ug/ml for imipenem and rifampin and 2 ,ug/ml for vancomycin against the inocula of 102 and 104 CFU/ml. Trimethoprim-sulfamethoxazole showed MIC90s of >25 ,ug/ml against all inocula tested.
Against the inoculum of 106 CFU/ml, coumermycin was slightly more active than the other agents, with MICs in the range of 0.5 to >4.0 ,ug/ml. At the largest inoculum size, the MBCs approximated the MICs or were slightly higher for all the antimicrobial agents tested ( Table 1) .
Combinations of coumermycin plus vancomycin, ciprofloxacin, or gentamicin were tested. Synergy was noted against 14% of the MRSA strains when coumermycin was combined with cephalothin or ciprofloxacin; synergy could not be demonstrated when coumermycin was combined with either vancomycin or gentamicin. Antagonism was noted only with the combination of coumermycin and gentamicin; 29% of the strains had a fractional inhibitory concentration index of 2.
The isolation of MRSA in hospitals has been on the rise throughout the United States (10) . Although the exact incidence has not been determined, in many hospitals MRSA represents from 5 to 10% of all staphylococcal isolates. At present, the drug of choice for the treatment of these infections is vancomycin. Coumermycin and vancomycin have different mechanisms of action. Coumermycin acts as an inhibitor of the B subunit of DNA gyrase (2), whereas vancomycin inhibits cell wall synthesis (5 Although the cephalosporins have been noted to be active in vitro against many MRSA, most investigators are not willing to use these agents to treat these infections. The aminoglycosides are effective in vitro against most MRSA, but few studies of their clinical efficacy have appeared in the literature (9) . Combinations of coumermycin and gentamicin, coumermycin and cephalothin, and coumermycin and ciprofloxacin show indifference in 43 to 57% of MRSA strains. It is possible that the use of combinations of antimicrobial agents is important in the treatment of these infections. Further clinical studies are warranted to examine the efficacy of coumermycin, either alone or in combination, in the treatment of infections due to MRSA.
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